Should We Abandon Nortriptyline for Functional Dyspepsia? Lessons From the TENDER Trial

Christian von Muhlenbrock, Aleks Israelyan, Tim Vanuytsel

Open source

DOI
10.1016/j.cgh.2026.08.023
Published
2026-09
Container
Clinical Gastroenterology and Hepatology
Publisher
Elsevier BV
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.cgh.2026.08.023,
  title = {Should We Abandon Nortriptyline for Functional Dyspepsia? Lessons From the TENDER Trial},
  author = {Christian von Muhlenbrock and Aleks Israelyan and Tim Vanuytsel},
  year = {2026},
  journal = {Clinical Gastroenterology and Hepatology},
  doi = {10.1016/j.cgh.2026.08.023},
  url = {https://doi.org/10.1016/j.cgh.2026.08.023}
}

RIS

TY  - JOUR
TI  - Should We Abandon Nortriptyline for Functional Dyspepsia? Lessons From the TENDER Trial
AU  - Christian von Muhlenbrock
AU  - Aleks Israelyan
AU  - Tim Vanuytsel
PY  - 2026
JO  - Clinical Gastroenterology and Hepatology
DO  - 10.1016/j.cgh.2026.08.023
UR  - https://doi.org/10.1016/j.cgh.2026.08.023
ER  - 

APA

Muhlenbrock, C. V., Israelyan, A., & Vanuytsel, T. (2026). Should We Abandon Nortriptyline for Functional Dyspepsia? Lessons From the TENDER Trial. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2026.08.023

Source records